The 2009-2014 World Outlook for BiologicsIcon Group International, Inc.September 20, 2008 194 Pages - SKU: ICN2097953 |
| Countries covered: Global This econometric study covers the world outlook for biologics across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the 230 countries of the world). This study gives, however, my estimates for the worldwide latent demand, or the P.I.E. for biologics. It also shows how the P.I.E. is divided across the world’s regional and national markets. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business. |
More Global Biopharmaceuticals Reports
Global Biosimilars Market Forecast to 2015 by
RNCOS
The biosimilars industry has been growing stupendously across the globe for past few years. Increasing healthcare costs and rising aging population are driving the industry, ...
Biosimilars: Current Situation & Future Prospects, Worldwide by
JustPharmaReports.com
The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this basis, prospects for biosimilars look good, with ...
World Biological Drugs Market 2012-2022 by
Visiongain
Where is the market for biological drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.
Our new study ...
Global Biosimilars: A return to optimism? by
Espicom Healthcare Intelligence
Despite some commentators predicting a muted or near nonexistent market for advanced biosimilars, many companies - and some surprising names - are positioning themselves for ...
Cell Culture: The World Market for Media, Sera and Reagents, 3rd. Edition by
Kalorama Information
Several cell culture-derived biopharmaceutical drugs were launched in the US and European markets in 2010. Biopharmaceuticals (recombinant proteins, monoclonal antibody and nucleic acid-based products) represent ...
See all reports like this >>
